Immunovant, Inc.
IMVT
Kedudukan dalam Saham
#3087
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Harga Saham
$28.32
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$5.85B
Perubahan (1 hari)
-0.94%
Perubahan (1 tahun)
49.85%
Negara
US
Perdagangan Immunovant, Inc. (IMVT)
Kategori
Healthcare
Sejarah harga saham bagi Immunovant, Inc. (IMVT)
Harga penutupan tertinggi: $30.02 pada 2026-10-01
Harga penutupan terendah: $9.88 pada 2019-06-01
Harga penutupan terendah: $9.88 pada 2019-06-01
Sejarah harga saham Immunovant, Inc. dari 2019 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 20.78% |
| 2025 | -7.38% |
| 2024 | -34.45% |
| 2023 | 163.89% |
| 2022 | 99.44% |
| 2021 | -84.02% |
| 2020 | 273.47% |
| 2019 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
